Exogene

About:

Exogene is a biotechnology company accelerating target & TCR discovery for cancer cell therapies using AI-enabled TCR-antigen screening.

Website: https://exogene.co.uk/

Top Investors: Entrepreneur First, Unruly Capital, R42 Group, Jude Gomila, Selvedge Venture

Description:

Exogene is a biotechnology company accelerating the discovery of T-cell-receptor(TCR)-based cancer immunotherapies for solid tumours by combining deep learning and high-throughput TCR-antigen screening. Exogene is building a computational platform to quickly and inexpensively identify new tumour targets shared across cancer patients, as well as safe and effective TCRs against these tumour targets for therapeutic application. Their mission is to develop better TCR-based immunotherapies, faster and at a fraction of the cost.

Total Funding Amount:

$2.11M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

London, England, United Kingdom

Founded Date:

2019-11-01

Founders:

Andrea Mambrini, Federico Paoletti

Number of Employees:

1-10

Last Funding Date:

2022-04-25

IPO Status:

Private

Industries:

© 2025 bioDAO.ai